APRIL inhibitors(Tumor necrosis factor ligand superfamily member 13 inhibitors), BAFF inhibitors(B-cell-activating factor/B lymphocyte stimulator inhibitors)

Therapeutic Areas

Immune System DiseasesUrogenital DiseasesSkin and Musculoskeletal Diseases+ [2]

Active Indication

Glomerulonephritis, IGALupus NephritisGlomerulonephritis, Membranous+ [7]

Inactive Indication

BlindnessClinically isolated syndromeColor Vision Defects+ [7]

Originator Organization

ZymoGenetics, Inc.

Active Organization

Vera Therapeutics, Inc.Merck Serono SA

Inactive Organization

Merck KGaAMerck Serono International SA

ZymoGenetics, Inc.

+ [1]

License Organization

Merck KGaA

Vera Therapeutics, Inc.

ZymoGenetics, Inc.

+ [1]

Drug Highest PhaseNDA/BLA

First Approval Date-

RegulationPriority Review (United States), Breakthrough Therapy (United States), Orphan Drug (European Union), Orphan Drug (Japan)

Structure/Sequence

Sequence Code 102889

Source: *****

Clinical Trials associated with Atacicept

NCT06983028

/ RecruitingPhase 2

A Phase 2 Study to Evaluate the Safety and Efficacy of Atacicept in Multiple Autoimmune Glomerular Diseases (PIONEER)

The purpose of this study is to evaluate the safety and tolerability of atacicept in adult and adolescent participants and to measure the effect in reducing proteinuria and preserving renal function.

Start Date07 Jul 2025

Sponsor / Collaborator

Vera Therapeutics, Inc.

NCT07020923

/ RecruitingPhase 2

A Study Evaluating Monthly (Every 4 Weeks) Dosing of Atacicept in Patients With IgAN

This is a Phase 2, open-label, multicenter, randomized study comprising parallel groups of participants receiving weekly and/or monthly doses of atacicept

Start Date29 May 2025

Sponsor / Collaborator

Vera Therapeutics, Inc.

NCT06674577

/ Enrolling by invitationPhase 2

A Multicenter, Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept

The purpose of this study is to collect long-term safety and tolerability data for atacicept in patients with IgAN that completed Vera trial investigating atacicept in IgAN population.

Start Date01 Dec 2024

Sponsor / Collaborator

Vera Therapeutics, Inc.

100 Clinical Results associated with Atacicept

100 Translational Medicine associated with Atacicept

100 Patents (Medical) associated with Atacicept

132

Literatures (Medical) associated with Atacicept

12 Feb 2026·NEW ENGLAND JOURNAL OF MEDICINE

A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy

Article

Author: Brenner, Robert M. ; Jha, Vivekanand ; Doan, Tom ; Maes, Bart ; Barratt, Jonathan ; Pal, Atanu ; Lafayette, Richard ; Liew, Adrian ; Suzuki, Hitoshi ; Barbour, Sean J. ; Kim, Beom Seok ; Trimarchi, Hernán ; Eren, Necmi ; Phoon, Richard K.S. ; Pecoits-Filho, Roberto ; Campbell, Kirk N. ; Tesař, Vladimir ; Wei, Xuelian ; Rizk, Dana V. ; Zhang, Hong ; Floege, Jürgen

BACKGROUND:

IgA nephropathy, the most common primary glomerulopathy worldwide, is a kidney disorder of B-cell origin characterized by mesangial accumulation of IgA-containing immune complexes. In at least 50% of patients, IgA nephropathy leads to kidney failure or death within 10 to 20 years after diagnosis. Atacicept is a native human transmembrane activator and calcium-modulator and cyclophilin-ligand interactor (TACI)-Fc fusion protein that inhibits two key immunoregulatory cytokines - B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) - that are thought to be central to the pathophysiology of IgA nephropathy.

METHODS:

In this ongoing, phase 3, multicenter, double-blind, randomized, placebo-controlled trial, we assigned patients with IgA nephropathy in a 1:1 ratio to receive atacicept at a dose of 150 mg once weekly, administered subcutaneously by patients at home, or matching placebo. The primary end point was the percentage change from baseline in the 24-hour urinary protein-to-creatinine ratio at week 36. Safety was also evaluated.

RESULTS:

A total of 203 patients were included in the prespecified interim analysis: 106 patients in the atacicept group and 97 in the placebo group. At week 36, the percentage reduction from baseline in the urinary protein-to-creatinine ratio was 45.7% in the atacicept group and 6.8% in the placebo group, with a geometric mean between-group difference of 41.8 percentage points (95% confidence interval, 28.9 to 52.3; P<0.001). Adverse events were observed in 59.3% of the patients in the atacicept group and in 50.0% in the placebo group; most were mild or moderate in severity.

CONCLUSIONS:

In this prespecified interim analysis, treatment with atacicept resulted in a significantly greater reduction in proteinuria than placebo at week 36 in patients with IgA nephropathy. (Funded by Vera Therapeutics; ORIGIN 3 ClinicalTrials.gov number, NCT04716231.).

22 Dec 2025·Cureus Journal of Medical Science

Emerging Therapies in IgA Nephropathy: From A Proliferation-Inducing Ligand (APRIL) and B-cell Activating Factor (BAFF) Inhibitors to Precision Medicine

Review

Author: Panta, Raju ; Sharma, Ishwor

IgA nephropathy (IgAN) is the most prevalent primary glomerular disease worldwide and a significant contributor to end-stage kidney disease (ESKD). Traditional management has centered on supportive care and non-specific immunosuppression, but recent advances in the understanding of pathogenic pathways have catalyzed the development of targeted therapies. This review synthesizes current evidence on evolving treatments, with a focus on A Proliferation-Inducing Ligand (APRIL) and B-cell Activating Factor (BAFF) (e.g., sibeprenlimab, atacicept, povetacicept, telitacicept), complement pathway modulators (e.g., iptacopan, cemdisiran, ravulizumab), and novel agents such as felzartamab and sparsentan. It also explores precision medicine strategies, including biomarker-guided therapy, individualized risk stratification, and combination regimens. Supported by high-quality recent clinical trial data and the latest kidney disease outcome guidelines, these innovations represent a paradigm shift toward personalized, disease-modifying treatment in IgAN, offering a new horizon for improved renal outcomes and long-term disease control.

02 Dec 2025·CURRENT MEDICAL RESEARCH AND OPINION

A plain language summary: long-term safety and effectiveness of atacicept in individuals with IgA nephropathy

Article

Author: Chen, Kelly ; Lafayette, Richard ; Barratt, Jonathan

129

News (Medical) associated with Atacicept

27 Mar 2026

·endpoints.news

Recursion appoints former Exelixis CMO; More executive moves at Incyte

→ Recursion has hired a new top doctor, bringing on Vicki Goodman as chief medical officer. Goodman previously served as CMO of the cancer biotechs Exelixis and Mural Oncology . She is taking over for David Mauro , who has been in the role for nearly three years. Goodman’s hiring is one of the biggest executive changes since Najat Khan took over as CEO at the start of 2026. → Pablo Cagnoni ’s job title at Incyte has been modified to president and global head of R&D, while longtime CMO Steven Stein will add to his responsibilities as head of late-stage development. CEO Bill Meury wasn’t done, naming J&J vet Mohamed Issa as head of US commercial. Issa had led the US oncology business and that won’t change with this role, but his leadership will extend to US immunology as well. Finally, Matteo Trotta — who came to Incyte in 2024 after 12 years at Novartis — is stepping down as US general manager, dermatology. Incyte has passed through Peer Review frequently since August, hiring a chief strategy officer, HR chief and general counsel. → Emil deGoma is a first-time CMO at Braveheart Bio , a new cardio bet that raised a $185 million Series A in November after doing a deal with Hengrui . The Akebia vet was SVP of medical research at Tourmaline Bio , which Novartis bought last year to boost a heart disease pipeline that already includes its blockbuster Entresto . “His background as an academic cardiologist and his industry experience advancing innovative medicines position him well to guide our clinical programs,” Braveheart CEO Travis Murdoch said in a statement. Murdoch sold HI-Bio to Biogen in 2024, and Braveheart is now chaired by Biogen CEO Chris Viehbacher . → David Marek quietly stepped down as CEO of ReAlta Life Sciences in October, according to his LinkedIn, and the Virginia-based biotech has tapped chairman Howard Berman as his successor. This is Berman’s first CEO appointment since he led Coya Therapeutics from 2020-24, and he has chaired the board at ReAlta since November. One more note: Madrigal Pharmaceuticals alum and ReAlta board member Kia Motesharei has been named president and COO. He had a short stint as an entrepreneur-in-residence at Formation Bio after more than two years with Madrigal as SVP, business & corporate development. → On March 30, Jennifer Jarrett will be president and CEO of Damora Therapeutics , which was purchased by Galecto and will carry on under the Damora name. Fairmount Funds founding partner Peter Harwin will chair the board, while Spyre Therapeutics CEO Cameron Turtle and ex- Blueprint Medicines finance chief Mike Landsittel are the newest board members. Jarrett had been a key member of the team at Arcus Biosciences in two separate stints since 2017, including the last five-plus years as COO. From 2019-20, she was head of corporate development and capital markets for Uber . You can also find her on the board of directors at Sagimet Biosciences , Syndax Pharmaceuticals and Zura Bio . → There’s a changing of the guard at Basel-based Anaveon . Andreas Katopodis is handing the CEO keys to Thaminda Ramanayake , who was recently chief business officer at CureVac , the mRNA biotech that he helped merge with rival BioNTech . Ramanayake is also a venture partner at the investment fund Entrée Bioventures . Anaveon is working on depleting pathogenic T cells for autoimmune diseases and inflammatory disorders. The company used to be clinical-stage with its initial goal of joining the IL-2 race , but that mission appears to have ended . Anaveon said it is backed by Syncona , Forbion , Blue Owl , Pontifax and the venture arms of Novartis and Pfizer . Anaveon’s chair is former Bayer CEO Dieter Weinand . → Two key execs have made their way to Averna Therapeutics , one of last year’s Endpoints 11 winners : CSO Robert Mabry worked for Averna CEO Tom Barnes in the same capacity at Orna Therapeutics , and Mabry has also been global head of biologics for Takeda . And Richard Morris has another CFO assignment following stints at Carisma Therapeutics , Passage Bio and Context Therapeutics . Averna’s focus on “jumping genes” — also known as retrotransposons — has additional competition . → France’s Abivax turned an experimental HIV drug ( obefazimod ) into a much-anticipated inflammatory disease treatment. As it prepares to take obefazimod to regulators, it has hired nine-year Takeda veteran Michael Nesrallah as its new chief commercial officer. Nesrallah filled multiple roles during his Takeda tenure, including general manager of Belgium, franchise head for IBD, leader of commercial operations for the US specialty business, and more. Obefazimod’s clinical success thus far in ulcerative colitis has drummed up M&A rumors. Alongside Nesrallah, Abivax also named Keith Fournier as SVP of global regulatory affairs and Maurus de la Rosa as SVP of research. Meanwhile, Sofinnova Partners ’ Kinam Hong stepped down from the board on March 19. → Led by ex- Prevail CEO Asa Abeliovich , neuro upstart Leal Therapeutics has brought in Johannes Tauscher as CMO, according to the search firm that helped with the appointment. Tauscher completed a dozen years with Takeda last summer and was the Japanese pharma’s global head of imaging. Leal broke cover in August with a $30 million Series A and a schizophrenia candidate called LTX-001 . → ADARx Pharmaceuticals has hopped aboard the banker-to-CFO train. The RNA startup poached Goldman Sachs healthcare investment banker Ryan Fisk , who will be chief financial and business officer at the San Diego biotech. Multiple other private drug developers have hired bankers to lead finance and help them go public. ADARx is a likely IPO candidate, since it’s already in Phase 3 with a hot drug modality, pharma validity with a major AbbVie pact , and backing from blue-chip investors like Bain Capital and TCGX . Fisk wrote to his LinkedIn following that he believes ADARx can be a “generational biotech company.” → For the third time this month , Peer Review is bringing you news of a Royalty Pharma hire. This time, decade-long IQVIA veteran Lucas Glass is becoming Royalty’s head of AI. “By incorporating intelligent automation, advanced analytics and AI-driven decision support, we are strengthening how we evaluate and invest in royalties and support our partners,” CEO Pablo Legorreta said in a statement . Glass was most recently SVP of technology at IQVIA. → Rani Therapeutics has selected ex- Radius Health chief Jesper Høiland as head of strategy. Høiland spent three decades at Novo Nordisk , and when Kelly Martin succeeded him at Radius Health, he became global chief commercial officer at Ascendis Pharma . He retired from Ascendis in 2022. → Mineralys Therapeutics has recruited Jeffrey Munsie as chief legal officer. Munsie previously held this position at two biotechs that have been acquired: Orbital Therapeutics (bought by Bristol Myers Squibb ) and Concert Pharmaceuticals (bought by Sun Pharma ). Will Mineralys be added to the list? Its aldosterone synthase inhibitor lorundrostat is showing promise in hypertension and has a Dec. 22 decision date with the FDA. → Atacicept maker Vera Therapeutics also has a new legal chief. Jane Wright-Mitchell spent more than two years with Vaxcyte as general counsel, chief compliance officer and corporate secretary, and she’s also worked on the legal teams at Mesoblast and Purdue Pharma . The FDA set a July 7 PDUFA date for atacicept in patients with IgA nephropathy. → Jennifer McDonough is getting started at Palvella Therapeutics as SVP of market access and patient services. McDonough was on the crew behind the commercial launch of the gene therapy Vyjuvek as SVP, patient access, analytics & operations at fellow Pennsylvania drugmaker Krystal Biotech . → Endpoints 11 winner Umoja Biopharma has welcomed Avenzo Therapeutics CEO Athena Countouriotis to the board of directors, along with Massachusetts General Hospital’s Marcela Maus . Countouriotis ran Turning Point Therapeutics until Bristol Myers scooped it up in 2022, and she’s also a board member at BioMarin , Iovance and Recludix Pharma , among others. → CAMP4 Therapeutics has elected Michael MacLean to the board of directors. MacLean is mapping out his next chapter after nearly six years as CFO of Avidity Biosciences , the RNA specialist that was sold to Novartis for $12 billion. → After retiring from Morgan Stanley in February, Jessica Chutter has joined the board of directors at PTC Therapeutics . Chutter had a 40-year career with Morgan Stanley, where she had been managing director and chair of biotechnology investment banking. Andrew Dunn also contributed to this edition.

Executive ChangeIPOAcquisition

25 Mar 2026

·www.biospace.com

Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer

BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Jane Wright-Mitchell, Pharm.D., J.D., as Chief Legal Officer, effective immediately. “Jane has worked with Vera Therapeutics previously as a strategic legal consultant and brings a depth and breadth of experience in supporting companies through regulatory approvals, commercialization, and intellectual property management,” said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. “As we near the potential launch of our first-in-class dual BAFF/APRIL inhibitor for patients with IgA nephropathy, Jane’s expertise will further strengthen our foundation for sustainable success.” “I look forward to partnering across the organization to lead our legal efforts through key milestones and the potential commercial launch of atacicept,” said Ms. Wright-Mitchell. “I am excited to join Vera Therapeutics' leadership and work towards our mission to advance treatments in order to change the standard of care for patients.” Ms. Wright-Mitchell is a business and compliance lawyer with over 25 years of experience advising public and private companies. She most recently served as a fractional general counsel supporting public and private companies in the life sciences industry. Ms. Wright-Mitchell was previously the General Counsel, Chief Compliance Officer and Corporate Secretary at Vaxcyte, Inc. (Nasdaq: PCVX). Prior to that role, she served as the Chief Legal Officer of other pharmaceutical and research companies. Ms. Wright-Mitchell holds a Bachelor of Science in Biological Sciences from Clemson University, a Pharm.D. from the University of Illinois, Chicago and a J.D. from Chicago Kent College of Law. She is a registered pharmacist as well as registered to practice before the United States Patent and Trademark Office. About Vera Therapeutics Vera Therapeutics is a biotechnology company focused on developing treatments for serious immunological diseases. Vera Therapeutics’ mission is to advance treatments that target the source of disease in order to change the standard of care for patients. Vera Therapeutics’ lead product candidate is atacicept, a fusion protein self-administered at home as a subcutaneous once weekly injection that blocks both B-cell Activating Factor (BAFF) and A Proliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgA nephropathy (IgAN) and lupus nephritis. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove clinically meaningful. In addition, Vera Therapeutics holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B-cell–mediated diseases. Vera Therapeutics is also evaluating the development of MAU868, a monoclonal antibody designed to neutralize infection with BK virus, which can have devastating consequences in kidney transplant recipients. Vera Therapeutics retains all global developmental and commercial rights to atacicept, VT-109, and MAU868. For more information, please visit . Forward-looking Statements Statements contained in this press release regarding matters, events or results that may occur in the future are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, Vera Therapeutics’ ability to launch a potential first-in-class dual BAFF/APRIL inhibitor for patients with IgA nephropathy; the Chief Legal Officer’s ability to further strengthen Vera Therapeutics’ foundation for sustainable success; and the plans, commitments, aspirations and goals under the caption “About Vera Therapeutics”. Words such as “believe,” “expect,” “may,” “plan,” “potential,” “will” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Vera Therapeutics’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks related to the regulatory approval process, results of earlier clinical trials may not be obtained in later clinical trials, preliminary results may not be predictive of topline results, risks and uncertainties associated with Vera Therapeutics’ business in general, the impact of macroeconomic and geopolitical events, and the other risks described in Vera Therapeutics' filings with the U.S. Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Vera Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. Investor Contact: Joyce Allaire LifeSci Advisors 212-915-2569 jallaire@lifesciadvisors.com Media Contact: Debra Charlesworth Vera Therapeutics 415-854-051 corporatecommunications@veratx.com

Executive ChangeLicense out/in

23 Mar 2026

·www.biospace.com

Tang Seizes Control of Aurinia, Taking CEO Post in Total Transformation of C-Suite

iStock, rudall30 Healthcare investor Kevin Tang and his allies now hold almost every leadership position at Aurinia Pharmaceuticals, the company at the heart of former CDER Director George Tidmarsh’s exit from the FDA. Six months after clashing with former Center for Drug Evaluation and Research Director George Tidmarsh over his comments regarding Aurinia Pharmaceuticals, Kevin Tang is taking over as CEO of the company—and has appointed his associates to other key positions. Tang, who has been chair of Aurinia’s board of directors since 2024, has replaced Peter Greenleaf as CEO, the company announced Monday . The new CEO is president of Tang Capital Management, an investment group that made its name offering an exit route to troubled biotechs. Tang Capital has built a position in Aurinia in recent years, growing its stake from 5.1% in September 2024 to 9.2% by late last month. The investment group has now secured control of Aurinia’s C-suite. Tang’s appointment as CEO is part of sweeping changes that have given other Tang Capital employees key roles in Aurinia’s leadership team. Ryan Cole is Aurinia’s new chief operating officer; Michael Hearne has joined as chief financial officer and Thomas Wei is the new chief scientific officer. Cole has worked at Tang Capital since 2014, while Hearne and Wei joined the investment company in 2015. They join Stew Kroll, Aurinia’s chief development officer who has worked at Tang Capital since 2016. According to Aurinia’s current leadership page, Kroll joined the biotech last year. Kroll’s appointment by Aurinia was not announced, and he is not listed on an archived version of the company’s leadership page that was live last month. Mergers & acquisitions Tang Capital’s Concentra on Buyout Binge With Plenty of Biotech Fodder After a slow 2024, the biotech shell company Concentra Biosciences is back, offering to buy four biotechs in the past month and seven so far this year. August 13, 2025 · 4 min read · Annalee Armstrong Read more Greenleaf, who spent seven years as Aurinia CEO, is one of several executives who are leaving the biotech as part of the changes. Chief Operating Officer Matthew Donley, Chief Medical Officer Gregory Keenan and Chief Financial Officer Joseph Miller are all following Greenleaf out the door. Donley, Miller and Keenan joined Aurinia in 2019, 2020 and 2023, respectively. Stephen Robertson will continue as general counsel, Aurinia said Monday. Robertson joined Aurinia in 2020, making him the most senior person still left at the company who arrived before the Tang era. The new-look leadership team takes over as the company focuses on growing sales of lupus nephritis treatment Lupkynis, the target of a social media attack from Tidmarsh. Last fall, Tidmarsh posted to LinkedIn that Lupkynis’ active ingredient vocolosporin had “significant toxicity” and that it had “not been shown to provide a direct clinical benefit for patients.” The post, which was quickly removed, prompted Tang to complaint with the FDA, which was ultimately handed off to the Office of Inspector General. Aurinia also filed a lawsuit that accused Tidmarsh of a “longstanding personal vendetta against Kevin Tang.” In the end, Tidmarsh left the agency amid an investigation into his “personal conduct.” Regulatory FDA’s Tidmarsh Singles Out Aurinia’s Drug in LinkedIn Post About Surrogate Endpoints Without naming Aurinia Pharmaceuticals, the CDER director in a now-deleted LinkedIn post claimed that for lupus nephritis, companies have not conducted post-approval studies “to demonstrate a benefit on hard clinical endpoints.” September 30, 2025 · 2 min read · Tristan Manalac Read more In addition to Lupkynis’ growth, Aurinia is working on showing that its investigational drug aritinercept is a challenger in a competitive autoimmune disease market. Aritinercept is a dual inhibitor of BAFF and APRIL, a mechanism it shares with Vertex’s povetacicept and Vera Therapeutics’ atacicept. Vertex and Vera could win FDA approval for their drugs in immunoglobulin A nephropathy this year. Jefferies analysts said last year that Aurinia’s drug candidate looks at least as good as povetacicept on all measures. Aurinia recently forecast sales of $305 million to $315 million this year, compared to $271 million in 2025. Jefferies analysts said in a February note to investors that the outlook could be considered conservative.

Executive ChangeDrug Approval

100 Deals associated with Atacicept

External Link

KEGG	Wiki	ATC	Drug Bank
D09704	Atacicept	-	DB06399

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glomerulonephritis, IGA	NDA/BLA	United States	Vera Therapeutics, Inc.	07 Jan 2026
Pain	Phase 3	United Kingdom	-	04 Jan 2008
Systemic Lupus Erythematosus	Phase 3	United States	Merck KGaA	01 Jan 2008
Systemic Lupus Erythematosus	Phase 3	Argentina	Merck KGaA	01 Jan 2008
Systemic Lupus Erythematosus	Phase 3	Australia	Merck KGaA	01 Jan 2008
Systemic Lupus Erythematosus	Phase 3	Austria	Merck KGaA	01 Jan 2008
Systemic Lupus Erythematosus	Phase 3	Bulgaria	Merck KGaA	01 Jan 2008
Systemic Lupus Erythematosus	Phase 3	Croatia	Merck KGaA	01 Jan 2008
Systemic Lupus Erythematosus	Phase 3	Czechia	Merck KGaA	01 Jan 2008
Systemic Lupus Erythematosus	Phase 3	France	Merck KGaA	01 Jan 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04716231 (ORIGIN 3, N Engl J Med \| ASN2025 \| GlobeNewswire) Manual	Phase 3	Glomerulonephritis, IGA	203	Atacicept 150 mg	tehuyfmbuh(zjknowwdgt) = mjnlhogcvn mwbaeiutlg (btjkyhbfxf ) View more	Positive	06 Nov 2025
				Placebo	tehuyfmbuh(zjknowwdgt) = kbhajnhfll mwbaeiutlg (btjkyhbfxf ) View more
NCT04716231 (ORIGIN, GlobeNewswire) Manual	Phase 2	Glomerulonephritis, IGA	116	Atacicept	nicjqywdbn(octoscgmol) = uxzghmvnoq ucdnwlplab (frohzkhzqs ) View more	Positive	26 Oct 2024
				Placebo	-
ISN WCN2024	Not Applicable	Glomerulonephritis, IGA	-	Atacicept 150 mg	urbijinzvm(iidmhthyvd) = cqvqigqvjs vqtpdvtrfx (owrojhgttr )	-	01 Apr 2024
				Placebo	urbijinzvm(iidmhthyvd) = dwqosehqzp vqtpdvtrfx (owrojhgttr )
NCT04716231 (ORIGIN, Literature) Manual	Phase 2	Glomerulonephritis, IGA	116	atacicept 25 mg	lgdmmdlgyv(cyccfjhtkv) = similar across the atacicept dose groups and placebo. shrzjyffkg (kwjxdvszpc )	Positive	27 Mar 2024
				atacicept 75 mg
NCT04716231 (ORIGIN, GlobeNewswire) Manual	Phase 2	Glomerulonephritis, IGA	-	Atacicept	ukbqatioao(nhjrzyhfru) = met its primary endpoint xxwkelrqyo (epdmtcwdnr ) Met View more	Positive	08 Jan 2024
				Placebo
NCT04716231 (ORIGIN \| JANUS, GlobeNewswire) Manual	Phase 2	Glomerulonephritis, IGA	-	atacicept (JANUS)	truzcjhkjr(dlnyxysuuz) = Through the randomized, placebo-controlled period, infections were balanced between atacicept and placebo in both the Phase 2a JANUS and Phase 2b ORIGIN studies. ofzwzkbipn (zaqemduvud )	Positive	04 Nov 2023
				placebo (JANUS)
NCT02808429 (Phase II study, CTgov)	Phase 2	Glomerulonephritis, IGA	16	Placebo (Placebo)	cqwupihmau = oldhekakur fzgsoddelh (cddecguuhx, qweslhutyf - swhdknvylo) View more	-	25 Feb 2021
				Atacicept 25 mg (Atacicept 25 mg)	cqwupihmau = xikfoiyizs fzgsoddelh (cddecguuhx, sjhuxwfgvh - tllpvypbzv) View more
NCT02070978 (ADDRESS II, Pubmed \| Rheumatology (Oxford))	Phase 2	Systemic Lupus Erythematosus	253	Atacicept 75 mg	qbdmbxhzpo(ejjcbromtz) = gwjoigkewc rblvffyzxu (bnsoitidba ) View more	-	06 Feb 2021
				Atacicept 150 mg	qbdmbxhzpo(ejjcbromtz) = vnzjysjfvf rblvffyzxu (bnsoitidba ) View more
NCT02808429 (Phase II study, ERA2020)	Phase 2	Proteinuria \| Glomerulonephritis, IGA Gd-IgA1	-	Placebo	jcmgftxntb(grgluoeerm) = xxrumawcnu hdqrnzdcsl (sxcqcrtpfi )	Positive	06 Jun 2020
				Atacicept 25mg	jcmgftxntb(grgluoeerm) = iqwbsmgzbs hdqrnzdcsl (sxcqcrtpfi )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis